Literature DB >> 26625365

Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children?

Chad A Knoderer1, Kristen R Nichols2, Kelsey C Lyon3, Megan M Veverka4, Amy C Wilson5.   

Abstract

BACKGROUND: In 2008, the empiric vancomycin dosing recommendation in children at our institution was changed from 40 to 60 mg/kg per day. Subsequently, an increased incidence of acute kidney injury (AKI) in patients receiving vancomycin was suspected. The objective of this study was to evaluate AKI in children receiving vancomycin and to determine risk factors for AKI development.
METHODS: Medical records of patients aged 30 days through 17 years who received vancomycin for at least 72 hours between January and December 2007 (40 mg/kg per day) and January and December 2010 (60 mg/kg per day) were reviewed. Patients with cystic fibrosis, an elevated baseline serum creatinine, or without a serum creatinine concentration obtained after receipt of vancomycin were excluded. Acute kidney injury was defined using adapted pediatric RIFLE criteria as an increase in serum creatinine from baseline of 50% or more.
RESULTS: Acute kidney injury occurred in 19.4% of the 859 children included, with no difference between the 2007 and 2010 periods (18.8% vs 20%, respectively; P = .636). Intensive care unit admission (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.20-2.94) and an initial vancomycin trough concentration ≥15 mg/L (OR, 2.18; 95% CI, 1.21-3.92) were determined to be significantly associated with AKI.
CONCLUSIONS: These results suggest an initial vancomycin serum trough concentration of ≥15 mg/L and intensive care unit admission are predictors of AKI in this pediatric population.
© The Author 2013. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  acute kidney injury; nephrotoxicity; pediatric; vancomycin

Year:  2013        PMID: 26625365     DOI: 10.1093/jpids/pit076

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  18 in total

1.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

2.  Increased Vancomycin Exposure and Nephrotoxicity in Children: Therapeutic Does Not Mean Safe.

Authors:  Kevin J Downes; Stuart L Goldstein; Alexander A Vinks
Journal:  J Pediatric Infect Dis Soc       Date:  2014-12-29       Impact factor: 3.164

3.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

4.  Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Authors:  Yilun Sun; Rachael L Huskey; Li Tang; Hiroto Inaba; Aditya H Gaur; Raul Ribeiro; Jeffrey E Rubnitz; Joshua Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  A whole blood microsampling assay for vancomycin: development, validation and application for pediatric clinical study.

Authors:  Ganesh S Moorthy; Kevin J Downes; Christina Vedar; Athena F Zuppa
Journal:  Bioanalysis       Date:  2020-09-18       Impact factor: 2.681

6.  Frequency of and Risk Factors for Acute Kidney Injury Associated With Vancomycin Use in the Pediatric Intensive Care Unit.

Authors:  Sarah Bonazza; Lauren C Bresee; Timothy Kraft; B Catherine Ross; Deonne Dersch-Mills
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Nov-Dec

7.  Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.

Authors:  Nicholas M Fusco; Calvin J Meaney; Corey Wells; Carla A Frederick; William A Prescott
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

8.  Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2017-05-05       Impact factor: 7.124

9.  Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.

Authors:  J Chase McNeil; Eric Y Kok; Andrea R Forbes; Linda Lamberth; Kristina G Hulten; Jesus G Vallejo; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

10.  Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children.

Authors:  Jennifer Le; Pamela Ny; Edmund Capparelli; James Lane; Becky Ngu; Richard Muus; Gale Romanowski; Tiana Vo; John Bradley
Journal:  J Pediatric Infect Dis Soc       Date:  2014-11-03       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.